



Zenlabs Ethica Ltd.

CIN NO. : L74900CH1993PLC033112, GSTIN NO. : 03AAFCS6226G1ZL

Regd. Office : Plot No. 194-195, 3rd Floor, Industrial Area, Phase-II, Chandigarh -160 002

Tel. : 0172-465 1105, Fax : 0172-265 6855

E-mail: queries@zenlabsethica.com, Website : www.zenlabsethica.com

PART I: STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 TH SEPTEMBER 2022						
Sr. No	Particulars	(₹ in Lakhs except EPS data)				
		Quarter Ended			Half Year Ended	
		9/30/2022	6/30/2022	9/30/2021	9/30/2022	9/30/2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Revenue from Operations	1,753.43	1,735.39	1,833.19	3,488.82	3,723.55
2	Other Income	3.24	2.10	3.63	5.34	5.69
3	Total Income (1+2)	1,756.67	1,737.49	1,836.82	3,494.16	3,729.24
4	Expenditure					
	a) Purchase of stock in trade	1,419.18	1,224.66	1,604.40	2,643.84	3,136.52
	b) (Increase)/decrease in stock-in-trade	(23.71)	150.98	(143.15)	127.27	(120.68)
	c) Employees benefit expenses	110.24	115.11	76.25	225.35	141.85
	d) Finance costs	12.72	11.54	2.16	24.26	2.97
	e) Depreciation and Amortisation	32.19	29.50	5.61	61.69	11.23
	f) Other Expenditure	151.52	155.04	251.32	306.56	476.86
	Total Expenses	1,702.14	1,686.83	1,796.59	3,388.97	3,648.75
5	Profit before Exceptional & Extraordinary Items (3-4)	54.53	50.66	40.23	105.19	80.49
6	Exceptional Items	-	-	-	-	-
7	Profit Before Tax (5-6)	54.53	50.66	40.23	105.19	80.49
8	Tax Expenses					
	a) Current Tax	14.23	15.51	2.50	29.74	12.56
	b) MAT Credit entitlement	-	-	(4.29)	-	(4.29)
	c) Deferred Tax	(1.13)	(1.41)	16.94	(2.54)	16.94
9	Profit(+)/ Loss(-) for the period (7-8)	41.43	36.56	25.08	77.99	55.28
10	Other Comprehensive Income					
	Items that will not be reclassified to profit or loss					
	Re-measurement of the net defined benefit plans	0.63	0.84	(1.59)	1.47	(1.54)
	Tax on above	(0.18)	(0.23)	0.40	(0.41)	0.40
11	Total Other comprehensive Income, net of tax	0.45	0.61	(1.19)	1.06	(1.14)
12	Total comprehensive Income for the period	41.88	37.17	23.89	79.05	54.14
13	Paid up equity share capital	651.00	651.00	651.00	651.00	651.00
	(Face Value of ₹ 10/- each per share)					
14	Basic and diluted Earning Per Share (EPS) after Extra Ordinary Items					
	-Basic	0.64	0.56	0.39	1.20	0.85
	-Diluted	0.64	0.56	0.39	1.20	0.85

NOTES :

- The above financial results for the quarter and half year ended 30th September, 2022 have been reviewed by the Audit Committee and were approved and taken on record by the Board of Directors in their respective meeting held on 18th October 2022. The statutory auditors of the Company have expressed an unmodified opinion in limited review report on.
- The Standalone financial results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The Company is considered to be a single segment company engaged in the trading of pharmaceuticals formulation. Consequently, the Company has, in its primary segment, only one reportable business segment. Accordingly, there are no separate reportable segments as required under Ind AS 108 "Operating Segment".

By order of Board
for Zenlabs Ethica Limited

Sanjay Dhir

DIN 02452461

Place: Chandigarh

Date: 18th October, 2022

Whole Time Director cum Chief Financial Officer